[go: up one dir, main page]

Bam et al., 2019 - Google Patents

Affibody-indocyanine green based contrast agent for photoacoustic and fluorescence molecular imaging of B7–H3 expression in breast cancer

Bam et al., 2019

View PDF
Document ID
2148984425991453150
Author
Bam R
Laffey M
Nottberg K
Lown P
Hackel B
Wilson K
Publication year
Publication venue
Bioconjugate chemistry

External Links

Snippet

Spectroscopic photoacoustic (sPA) molecular imaging has high potential for identification of exogenous contrast agents targeted to specific markers. Antibody–dye conjugates have recently been used extensively for preclinical sPA and other optical imaging modalities for …
Continue reading at pmc.ncbi.nlm.nih.gov (PDF) (other versions)

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group
    • A61K49/0021—Fluorescence in vivo characterised by the fluorescent group the fluorescent group being a small organic molecule
    • A61K49/0032—Methine dyes, e.g. cyanine dyes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives
    • A61K47/48—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates
    • A61K47/48369—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates the modifying part being an antibody, an immunoglobulin, or a fragment thereof, e.g. a Fc-fragment
    • A61K47/48507—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates the modifying part being an antibody, an immunoglobulin, or a fragment thereof, e.g. a Fc-fragment the modifying agent being a well defined antibody or immunoglobulin bearing at least one antigen-binding site
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay
    • G01N33/574—Immunoassay; Biospecific binding assay for cancer
    • G01N33/57407—Specifically defined cancers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation; Therapies using these preparations

Similar Documents

Publication Publication Date Title
Bam et al. Affibody-indocyanine green based contrast agent for photoacoustic and fluorescence molecular imaging of B7–H3 expression in breast cancer
Nessler et al. Increased tumor penetration of single-domain antibody–drug conjugates improves in vivo efficacy in prostate cancer models
Chen et al. In vivo tumor vasculature targeted PET/NIRF imaging with TRC105 (Fab)-conjugated, dual-labeled mesoporous silica nanoparticles
Ou et al. Multimodal multiplexed immunoimaging with nanostars to detect multiple immunomarkers and monitor response to immunotherapies
Wilson et al. Spectroscopic photoacoustic molecular imaging of breast cancer using a B7-H3-targeted ICG contrast agent
Chakravarty et al. Nanobody: the “magic bullet” for molecular imaging?
Simon et al. Orthogonal assembly of a designed ankyrin repeat protein–cytotoxin conjugate with a clickable serum albumin module for half-life extension
Schmidt et al. A modeling analysis of the effects of molecular size and binding affinity on tumor targeting
Hong et al. Multimodality imaging of breast cancer experimental lung metastasis with bioluminescence and a monoclonal antibody dual-labeled with 89Zr and IRDye 800CW
Foersch et al. Molecular imaging of VEGF in gastrointestinal cancer in vivo using confocal laser endomicroscopy
Wissler et al. Site-specific immuno-PET tracer to image PD-L1
Sato et al. Role of fluorophore charge on the in vivo optical imaging properties of near-infrared cyanine dye/monoclonal antibody conjugates
Wang et al. Noncanonical amino acids as doubly bio-orthogonal handles for one-pot preparation of protein multiconjugates
Abou-Elkacem et al. Thy1-targeted microbubbles for ultrasound molecular imaging of pancreatic ductal adenocarcinoma
Sato et al. Impact of C4′-O-alkyl linker on in vivo pharmacokinetics of near-infrared cyanine/monoclonal antibody conjugates
Shipunova et al. Comparative evaluation of engineered polypeptide scaffolds in HER2-targeting magnetic nanocarrier delivery
Dahlgren et al. Antibody-drug conjugates and targeted treatment strategies for hepatocellular carcinoma: a drug-delivery perspective
Reeßing et al. A facile and reproducible synthesis of near-infrared fluorescent conjugates with small targeting molecules for microbial infection imaging
England et al. ImmunoPET imaging of insulin-like growth factor 1 receptor in a subcutaneous mouse model of pancreatic cancer
Kruziki et al. 64Cu-labeled Gp2 domain for PET imaging of epidermal growth factor receptor
Pung et al. Generation of peptides using phage display technology for cancer diagnosis and molecular imaging
Godard et al. NIR-II aza-BODIPY dyes bioconjugated to monoclonal antibody trastuzumab for selective imaging of HER2-positive ovarian cancer
Gerke et al. Clickable albumin nanoparticles for pretargeted drug delivery toward PD-L1 overexpressing tumors in combination immunotherapy
Olson et al. Preclinical evaluation of a humanized, near-infrared fluorescent antibody for fluorescence-guided surgery of MUC16-expressing pancreatic cancer
Lim et al. Targeted hyperbranched nanoparticles for delivery of doxorubicin in breast cancer brain metastasis